obesity drugs

Novo Nordisk A/S (NYSE:NVO) Chief Executive Officer (CEO) Mike Doustdar said the company’s obesity medicines may have uses beyond weight loss as researchers continue studying the broader effects of semaglutide. "We have to be obsessed with what our patients want," Doustdar said Sunday in an...

Big pharma is currently facing a potential “bubble effect” due to the surging demand for weight loss and diabetes drugs, as revealed in a report by Deloitte released on Monday. Drugs such as Novo Nordisk‘s (NYSE:NVO) Wegovy and Eli Lilly’s (NYSE:LLY...

Hims & Hers Health Inc. (NYSE:HIMS) said it is broadening access to FDA-approved weight loss treatments as shifting market dynamics around GLP-1 drugs drive demand for more flexible and affordable options. The company outlined a strategic shift in its U.S. weight loss business, emphasizing...

Wave Life Sciences Ltd. (NASDAQ:WVE) shares are tumbling on Thursday following the announcement of interim Phase 1 data from its INLIGHT trial. Six-Month Data Shows Visceral Fat Reduction And Lean Mass Stability At the six-month follow-up, a single 240 mg dose of WVE-007 demonstrated significant...

The United Laboratories International Holdings Limited and Novo Nordisk A/S (NYSE:NVO) reported Wednesday topline data from a phase 2 trial in China showing that UBT251, a triple receptor agonist. Semaglutide is a key ingredient in the famed Wegovy and Ozempic. UBT251 is designed to challenge Eli...

Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) shared additional data from the Phase 3 TRANSCEND trial of setmelanotide. The stock’s movement comes as the company highlighted an 18.8% placebo-adjusted difference in BMI reduction achieved in all patients at 52 weeks, contributing to a positive...

Novo Nordisk A/S (NYSE:NVO) on Monday said the Wegovy pill is now available, which was approved in December 2025. Novo Nordisk stock is charging ahead with explosive momentum. What’s fueling NVO momentum? Wegovy pill showed an average weight loss of about 17% (16.6%) when used along...

Novo Nordisk A/S (NYSE:NVO) presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Cardiology (ESC) Congress 2025. The STEER study investigated the risk of major adverse cardiovascular events (MACE) with Wegovy (...

Eli Lilly and Co (NYSE:LLY) on Tuesday shared detailed results from the Phase 3 ATTAIN-1 trial, evaluating the safety and efficacy of oral orforglipron in adults with obesity, or overweight with a weight-related medical problem, and without diabetes. At 72 weeks, all three doses (6 mg, 12 mg, and...

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

Vivani Medical, Inc. (NASDAQ:VANI) and Okava Pharmaceuticals, Inc. expanded their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, diabetes and other cardiometabolic conditions. Financial terms of the expanded agreement were not...

In a bid to meet escalating demand for its obesity drugs, pharmaceutical behemoth, Eli Lilly & Co. (NYSE:LLY) has funneled $800 million into its Irish operations to ramp up the production of its blockbuster drugs, Mounjaro and Zepbound. What Happened: The investment is aimed at ensuring a...

Vivani Medical Inc. (NASDAQ:VANI) expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024. The NPM-115 clinical program will evaluate the investigational 6-month GLP-1 implant for chronic weight management in patients who are either obese or...

An analysis of U.S. pharmacy claims data reveals that only one in four patients prescribed Novo Nordisk A/S’s (NYSE:NVO) weight-loss drugs, Wegovy and Ozempic, continue their treatment after two years. The data provided to Reuters highlights a significant decline in long-term adherence to...

The World Health Organization (WHO) has cautioned that the increasing global obesity crisis, which now affects over a billion people, cannot be resolved by the use of obesity medications alone. What Happened: The WHO has warned that the use of effective and popular obesity medications will not be...